Molecular Targets for the Treatment of Metastatic Colorectal Cancer.
Romain CohenThomas PudlarzJean-François DelattreRaphaël ColleThierry AndréPublished in: Cancers (2020)
Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), RAS and BRAF mutations, HER2 amplification or NTRK fusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI, HER2, NTRK).
Keyphrases
- metastatic colorectal cancer
- small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- tyrosine kinase
- primary care
- newly diagnosed
- chronic kidney disease
- ejection fraction
- squamous cell carcinoma
- healthcare
- single molecule
- prognostic factors
- peritoneal dialysis
- genome wide
- gene expression
- wild type
- single cell
- quality improvement
- combination therapy
- nucleic acid
- ultrasound guided